Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.

Name: Αlpha¹ Rigor Record — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.
Item: Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.
Rating: 100
Author: Αlpha¹

Stanley C, Mallik R, Hamid N, Jassil FC, Reuven V, Ruwona T, Dicken SJ, Qamar S, Norton B, Kingett H, Pucci A, Magee C, Boniface D, Batterham RL, Devalia K, Mok J, Elkalaawy M, Loy J, Jenkinson A, Markakis H, Adamo M, Brown A, Makaronidis J

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.5★ (Adequate), 0 critical, 2 high issues for “Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced3 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported randomized controlled trial with rigorous design, clear ethical approvals, and comprehensive reporting. Minor internal inconsistencies in adverse event counts and a slightly overstated claim about rivaling revisional surgery are the main weaknesses.

Both reviewers classified the study as interventional, and this was adopted. The evaluation covered the full text, with verification of statistics (7 tests recomputed consistently), citations (no retracted or not-found references), and reproducibility (GitHub link live). The GRIM/GRIMMER checks were not applicable due to continuous outcomes.

6 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated), 1 only partially supported (evidence backs part of the claim; gaps or caveats remain).

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 7 tests: 7 consistent, 0 inconsistent; 2 recomputed directly from the reported test statistics, 5 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior studies (GRAVITAS, BARI-OPTIMISE, STEP program) and explains the rationale for testing semaglutide in this population. It acknowledges gaps, such as the lack of a randomized trial for semaglutide in post-bariatric patients with suboptimal response. Limitations of prior work are addressed by designing a trial with a longer duration and a more potent GLP-1RA.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited, a logical rationale, and addresses limitations of prior research.

Evidence

direct quote[Introduction, paragraphs 3-5]

“The GRAVITAS trial demonstrated that, in individuals with persistent or recurrent T2D after MBS, liraglutide 1.8 mg daily as an adjunct to lifestyle intervention, improved glycemic control with a mean weight difference of −4.2 kg (95% confidence interval (CI) −6.8 to −1.4) after 26 weeks.”